[Featured Stock] Vibozone Pharma Hits Consecutive 52-Week Highs... Soars on Hopes for 38th Domestic New Drug

Record-high rally on potential to become 'Domestic New Drug No. 38'
Most promising new drug candidate considering approval time
Opiranserin highlighted as non-narcotic analgesic alternative to opioids

Vivozon Pharmaceutical continues its streak of 52-week record highs. 'Ofiranserin' has emerged as a strong candidate for the 38th domestically developed new drug, leading the stock price into a full-fledged upward phase.

As of 11:02 AM on the 1st, Vivozon Pharmaceutical is trading at 6,840 KRW, up 10.14% (630 KRW) from the previous trading day. Since breaking the 5,000 KRW mark on the 25th of last month and setting a 52-week high, the stock has been gradually reaching higher peaks. Vivozon Pharmaceutical's stock price reaching the 6,000 KRW level is the first time since March 31, 2023.

Vivozon Pharmaceutical's 'Ofiranserin' applied for product approval from the Ministry of Food and Drug Safety (MFDS) in November last year, based on the results of domestic Phase 3 clinical trials. For a domestically developed new drug to be approved, it must complete preclinical (non-clinical) trials and Phase 1, 2, and 3 clinical trials, then submit the clinical trial report. Typically, the approval process takes about one year. Considering this, the review results are expected soon. Once approved by the MFDS, it will become the 38th domestically developed new drug.

Ofiranserin is a non-opioid analgesic in injectable form. It is used to relieve postoperative pain. In domestic Phase 3 clinical trials involving 285 patients experiencing pain after laparoscopic colon resection surgery, an average pain reduction effect of about 35% was observed. Currently, the only analgesics available for moderate to severe pain are opioid narcotics.